ClinicalTrials.gg
RecruitingNCT05659901Updated Nov 2, 2026

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

An observational study in Pelizaeus-Merzbacher Disease, sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 10 sites in 7 countries. Open to male participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Ionis Pharmaceuticals, Inc. · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.
Updated Oct 2, 2026First site in GermanyNo longer in Germany+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
6 Months to 17 Years
Sex
Male
01

Study summary

The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on clinical, participant, and caregiver-reported outcome assessments to inform the development of therapies for PMD.

Read the detailed description

This is a multi-center, non-randomized, non-interventional integrated prospective and retrospective study in up to 32 participants with PMD who can undergo general anesthesia or conscious sedation (if necessary) to collect fluid biomarkers (CSF and blood), neuroimaging, and clinical assessments to be used in support of the development of therapies for PMD. The study duration for each participant will be approximately 26 months (Week 106).

02

Conditions studied

  • Pelizaeus-Merzbacher Disease

Keywords

  • PMD
03

In context

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pelizaeus-Merzbacher disease participant population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has a parent or caregiver capable of providing (signed and dated) and able to attend all scheduled study visits and provide feedback regarding the participant's symptoms and performance as described in the protocol and be able to comply with all study requirements
  2. Participant has a diagnosis of Pelizaeus-Merzbacher Disease with genetic confirmation of PLP1 duplication
  3. Male, 6 months-17 years old, inclusive, at the time of informed consent and phenotype consistent with classic PMD
  4. No for lumbar punctures (LPs), blood draws, neuroimaging, sedation (if necessary) or other study procedures

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in medical history or physical examination
  2. > 2 copies of the PLP1 gene
  3. Have any other conditions, which, in the opinion of the investigator would make the participant unsuitable for inclusion, or could interfere with the participant taking part in or completing the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pelizaeus-Merzbacher Disease Participants

    Participants will undergo CSF collection and neuroimaging procedures, up to Week 106 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study period (up to 26 months).

06

What researchers measure

Primary outcomes

  1. Assess Longitudinal Changes in Fluid Biomarkers

    Changes in Proteolipid Protein 1 (PLP1) in CSF and disease related biomarkers

    Time frame: Up to 26 months

  2. Assess Longitudinal Changes in Neuroimaging Parameters

    Changes in regional brain volumes (MRI) and in brain metabolites (MRS)

    Time frame: Up to 26 months

  3. Assess longitudinal changes in performance on clinical, and patient and caregiver-reported outcome assessments

    Includes collection of gross and fine motor outcomes, spasticity, dysphagia, cognition and behavior, and sleep.

    Time frame: Up to 26 months

Secondary outcomes

  1. Characterize health service utilization and economic and disease burden

    Time frame: Up to 26 months

07

Study locations

7 of 10 sites recruiting
  • Ionis Investigative Site
    Atlanta, Georgia 30342, United States
    Recruiting
  • Ionis Investigative Site
    Baltimore, Maryland 21205, United States
    Recruiting
  • Ionis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Ionis Investigative Site
    Clermont-Ferrand, France
    Completed

    Not enrolling at this site.

  • Ionis Investigative Site
    Le Kremlin-Bicêtre, 94270, France
    Active, not recruiting

    Not enrolling at this site.

  • Ionis Investigative Site
    Göttingen, Germany
    Completed

    Not enrolling at this site.

  • Ionis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Ionis Investigative Site
    Milan, 20154, Italy
    Recruiting
  • Ionis Investigative Site
    Amsterdam, 1081 HV, Netherlands
    Recruiting
  • Ionis Investigative Site
    Leeds, LS1 3EX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Mar 2029, 77 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 21, 2022
StartActual
Oct 3, 2022
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed — first site in Germany; no longer in Germany
Show 3 added (1 United States, 1 France, 1 Germany)
  • Ionis Investigative Site · Baltimore, United States
  • Ionis Investigative Site · Clermont-Ferrand, France
  • Ionis Investigative Site · Göttingen, Germany
Show 2 removed
  • Ionis Investigative Site · Clermont-Ferrand, France
  • Ionis Investigative Site · Göttingen, Germany
across 2 updates, Oct 1, 2026 – Oct 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 2, 2026
    2 sites added — first site in Germany
    Show 2 added (1 France, 1 Germany)
    • Ionis Investigative Site · Clermont-Ferrand, France
    • Ionis Investigative Site · Göttingen, Germany
  3. Oct 1, 2026
    1 site added, 2 sites removed; no longer in Germany
    Show site
    • Ionis Investigative Site · Baltimore, United States
    Show 2 removed
    • Ionis Investigative Site · Clermont-Ferrand, France
    • Ionis Investigative Site · Göttingen, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05659901
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Oct 3, 2022
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Ionis Pharmaceuticals
Contact
IonisPelizaeusMerzbacherStudy@clinicaltrialmedia.com
(844) 430-1848

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion